Volume 48S Number 1

Volume 48S Number 2

Volume 48S Number 2

previous article

next article

Analysis of the significance of IIe 105Val polymorphism of the GSTP1 gene in the mechanism of development of vitiligo in the uzbek population living in the bukhara region

Sh. Z. Mavlyanova^a*, I. B. Shukurov^a, M. F. Yaxshiyeva^b, G. I. Boltayeva^b

 
ABSTRACT:     Vitiligo is the most common disease among skin diseases characterized by multifactoriality and immunomediation, in the pathogenesis of which genetic determinism plays an important role. Studies of allelic variants of the polymorphic variant IIe 105Val of the GSTP1 gene of the xenobiotic biotransformation enzyme in patients with vitiligo living in the Bukhara region of the Republic of Uzbekistan. 109 patients aged 5 to 57 years were examined. All patients underwent clinical, molecular genetic, and statistical studies. An analysis of molecular genetic studies of the second phase IIe 105 Val xenobiotics detoxification enzyme gene of the GSTP1 gene showed that the association of polymorphisms of the genotypes of the heterozygous A/G variant of the GSTP1 gene in the group of patients revealed an increase in indicators by 1.7 times compared to the control of healthy individuals. (χ2=2.02 p<0.36; OR=1.93; 95%CI 0.77-4.8).Taking into account the clinical form of vitiligo, the heterozygous variant A/G IIe 105 Val of the GSTP1 gene was most often detected in the group of patients with segmental - 30% and vulgar form of vitiligo - 20%, the unfavorable homozygous variant G/G - in patients with the acrofacial form -10.8 % of cases. The G allele and the heterozygous genotype of the IIe 105 Val polymorphism of the GSTP1 gene are markers of an increased risk of developing vitiligo in the population of the Bukhara region, especially a localized form of dermatosis. The A allele and the functionally favorable A/A genotype are reliable protective markers against the development of pathology (χ2=1.28 p<0.26; OR=0.67; 95% CI 0.34-1.34).

* Corresponding author, E-mail:

Received 18 Aug 2022, Accepted 13 Nov 2022